All News

The FDA okayed 2 breakthrough therapy designations for fam-trastuzumab deruxtecan-nxki in HER2-positive solid tumors and colorectal cancer, which are based on data from the phase 2 DESTINY-PanTumor02 and DESTINY-CRC02 trials.

Despite seeming to elicit more pathological complete responses in patients with hormone receptor–positive, HER2-negative triple-negative breast cancer receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.

Data from the phase 3 ASCEND trial and a phase 1/2 trial support the National Medical Products Administration’s approval of acalabrutinib in China as a treatment for chronic lymphocytic leukemia.

Patients with dyserythropoiesis appear to have higher PD-L1 expression than those without in a study population of those with myelodysplastic syndromes.

Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.

Real-world data suggest that the presence of pelvic lymphadenopathy should not be viewed as a contraindication to trimodality therapy in nonmetastatic clinically node-positive bladder cancer.

The safety profile of tisotumab vedotin-tftv among those with recurrent or metastatic cervical cancer in the phase 3 innovaTV 301 trial appears to be comparable with prior reports of the agent.

Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.

Results from a randomized trial suggest that neoadjuvant FOLFOX may be an effective treatment for patients with locally advanced rectal cancer who are suitable to undergo sphincter-sparing surgery.

Patients with low-grade serous ovarian cancer appear to have worse survival outcomes following treatment with neoadjuvant chemotherapy.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Findings from a real-world cohort study may support renewed attention to completing molecular genotyping before first-line therapy for patients with metastatic nonsquamous non–small cell lung cancer.

Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.

Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.

Prospective, real-world data indicate that most patients with colon or rectal cancer who undergo surgery remain independent.

Investigators assess edoxaban as part of a multicenter, open-label superiority trial in patients with active cancer and newly diagnosed isolate distal deep vein thrombosis.

Findings from the LUMINA study indicate that it may be feasible to omit radiotherapy in patients 55 years and over with T1N0, grade 1/2 luminal A breast cancer.

Investigators report no new safety signals with alectinib as a treatment for those with early-stage, ALK-positive non–small cell lung cancer in the phase 3 ALINDA study.

Jonathan Leeman, MD, indicates that the longer-follow is necessary to confirm late toxicities and disease control associated with adaptive radiotherapy in patients with prostate cancer.

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Investigators report that Tumor Treating Fields and standard of care therapy should be considered as a treatment for non–small cell lung cancer in the metastatic setting.

Investigators report that patients with relapsed/refractory myeloma treated with mezigdomide and dexamethasone primarily experienced myelotoxic effects.

Investigators also report an improvement in time to next intervention with vorasidenib compared with placebo among patients with IDH-mutated glioma in the phase 3 INDIGO trial.

Results from the phase 1/2 BEXMAB study assessing bexmarilimab show promising activity in patients with acute myeloid leukemia.

Data from the phase 3 KEYNOTE-811 trial highlight a trend towards improved overall survival among patients with HER2-positive, PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma receiving pembrolizumab, trastuzumab, and chemotherapy.

Findings from a multi-center phase 1/2 trial highlight only that only grade 1 cytokine release syndrome events occurred among patients with indolent non-Hodgkin lymphoma receiving MB-106.

Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.

Treatment with divarasib appears to produce a manageable safety profile of low-grade toxicities in patients with advanced or metastatic KRAS G12C–mutated solid tumors.

Increasing radiation doses to the whole heart appear to correlate with higher risks of valvular disease, coronary artery disease, and heart failure in childhood cancer survivors.

Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.